Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US92337C2035
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG001J2LSK5
VSTM
Verastem Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Verastem Inc
ISIN
US92337C2035
TICKER
VSTM
MIC
XNAS
REUTERS
VSTM.OQ
BLOOMBERG
VSTM US
Di., 23.06.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive preliminary data from the ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, with best-in-class potential...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Mi., 17.06.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1b/2a Recommended Phase 2 Dose (RP2D) cohort of 29 patients evaluating avutometinib plus defactinib in combination...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Di., 16.06.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial (NCT07644559) evaluating VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor wi...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Mo., 15.06.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor conference call and webcast on Tuesday, June 23 at 4:30 pm ET to report progress across the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D clinical program and upda...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Mi., 03.06.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to VS-7375, an oral and potential best-in-class investigational selective KRAS G12D (ON/OFF)...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Mi., 27.05.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. A live w...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Di., 26.05.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Michael P. Bailey to its Board of Directors. The Company also announced that Robert Gagnon stepped down from the Board following the end of his term on May 21, 2026...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Di., 12.05.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in New York City: HCW 4th Annual BioConnect Investor Conference: Tuesday, May...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Fr., 08.05.2026       Verastem
US92337C2035

Today, STAAR Low-Grade Serous Ovarian Cancer Foundation, Not These Ovaries, and Verastem Oncology announced the launch of the LGSOC Resource Guide, a unique resource designed to support patients living with low-grade serous ovarian cancer (LGSOC), a rare and distinct form of ovarian cancer, along with their caregivers and advocates. Available at w...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent business progress. “As we mark the one-year anniversary of the FDA-approval of AVMAPKI FAKZYNJA C...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 30.04.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the launch of its Reimagine Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) campaign for AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets), the first and only t...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Verastem
US92337C2035

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its first quarter 2026 financial results and business updates on Thursday, May 7, 2026, at 4:30 pm ET. A live aud...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink
Do., 08.05.2025       Verastem
US92337C2035

Instrument ID [16002413] (2VSA - US92337C2035) suspended...
Zur Nachricht
Verastem
Charts & Research Termsheets Terminal
Permalink